Date published: 2025-9-9

00800 4573 8000

SCBT Portrait Logo
Seach Input

Inhibiteurs eIF4B

eIF4B Inhibitors are a class of compounds that target the eukaryotic initiation factor 4B (eIF4B), a critical component of the translation initiation machinery in eukaryotic cells. eIF4B plays a key role in facilitating the recruitment of ribosomes to messenger RNA (mRNA), a process that is essential for the synthesis of proteins. Specifically, eIF4B enhances the helicase activity of eIF4A, another initiation factor, which unwinds secondary structures in the 5' untranslated region (UTR) of mRNA. This unwinding is necessary for the small ribosomal subunit to scan the mRNA and locate the start codon, thereby initiating translation. Inhibitors of eIF4B disrupt this process, potentially leading to a reduction in global protein synthesis, as well as selective effects on the translation of specific mRNAs that are particularly dependent on eIF4B activity.

Research into eIF4B Inhibitors is valuable for understanding the regulation of translation, a fundamental process that controls gene expression at the post-transcriptional level. By inhibiting eIF4B, scientists can investigate the effects on mRNA translation, especially those mRNAs with complex secondary structures in their 5' UTRs, which are more reliant on eIF4B for efficient translation. This can provide insights into how cells control the synthesis of proteins in response to various stimuli and conditions, such as stress, nutrient availability, and signaling pathways. Additionally, eIF4B is known to interact with other components of the translation initiation complex, including eIF3 and the cap-binding protein eIF4E, so its inhibition may shed light on the broader network of interactions that regulate translation initiation. Understanding these interactions is crucial for unraveling the complexities of translational control and its impact on cellular function, growth, and adaptation. Researchers can use eIF4B Inhibitors as tools to dissect these processes, thereby contributing to a deeper knowledge of how cells regulate protein production in both normal and altered states.

VOIR ÉGALEMENT...

Items  11  to  16  of  16 total

Afficher:

Nom du produitCAS #Ref. CatalogueQuantitéPrix HTCITATIONS Classement

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

Les dommages à l'ADN causés par la doxorubicine peuvent amener la cellule à donner la priorité à la réparation de l'ADN par rapport aux fonctions régulières, supprimant potentiellement la machinerie ARNi et diminuant les niveaux d'eIF2C2.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

L'inhibition de la topoisomérase I par la camptothécine peut causer des dommages à l'ADN, ce qui pourrait conduire à une réduction de l'attention portée aux processus ARNi et, par conséquent, à une diminution de l'expression de l'eIF2C2.

Geldanamycin

30562-34-6sc-200617B
sc-200617C
sc-200617
sc-200617A
100 µg
500 µg
1 mg
5 mg
$38.00
$58.00
$102.00
$202.00
8
(1)

En inhibant la Hsp90, la geldanamycine peut déstabiliser les protéines associées à l'ARNi, ce qui pourrait entraîner une diminution de la stabilité ou de la synthèse de l'eIF2C2.

Silvestrol

697235-38-4sc-507504
1 mg
$920.00
(0)

Composé naturel isolé de la plante Aglaia foveolata, connu pour sa puissante inhibition de l'EIF4AI.

Rocaglamide

84573-16-0sc-203241
sc-203241A
sc-203241B
sc-203241C
sc-203241D
100 µg
1 mg
5 mg
10 mg
25 mg
$270.00
$465.00
$1607.00
$2448.00
$5239.00
4
(1)

Un autre composé naturel trouvé dans plusieurs plantes, telles que le genre Aglaia, avec une forte activité inhibitrice de l'EIF4AI.

4E1RCat

328998-25-0sc-361085
sc-361085A
10 mg
50 mg
$189.00
$797.00
(0)

Inhibiteur synthétique de l'EIF4AI conçu pour perturber le complexe eIF4F, inhibant ainsi la traduction cap-dépendante.